The article examines the objective, findings, and clinical context described in FDA approves neladalkib for ALK-positive lung cancer.
Approach:
Approval: The FDA granted accelerated approval to neladalkib (Nelkarmi) on November 17 for specified previously treated patient groups.
Evidence: Approval was supported by ALKOVE-1, a multicenter, single-arm, open-label trial of 222 patients. Confirmed response rates and duration of response were assessed using RECIST 1.1 with blinded independent central review.
Administration and safety: Neladalkib is taken orally at 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.
Key Findings:
Among 67 patients whose only prior ALK TKI was alectinib, the confirmed overall response rate was 49%; 76% of responders maintained response for at least 6 months and 52% for at least 12 months.
Among 155 patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy, the confirmed overall response rate was 32%; 69% of responders maintained response for at least 6 months and 51% for at least 12 months.
Warnings include hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity. Adverse reactions reported in at least 20% included musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, fatig…
Interpretation:
The approval covers adults with locally advanced or metastatic ALK-positive NSCLC previously treated either with alectinib as their only ALK TKI in the unresectable locally advanced or metastatic setting, or with at least 2 ALK TKIs and platinum-based chemotherapy.
Limitations:
ALKOVE-1 was single-arm and did not include a randomized comparator group.
Conclusion:
The FDA also granted the application priority review and neladalkib breakthrough therapy and orphan drug designations.